GRI Bio (GRI) Return on Capital Employed (2021 - 2026)
GRI Bio (GRI) posted quarterly Return on Capital Employed of 118.68% for Q1 2026, up 32612.0% year-over-year from N/an in Q1 2025, and up 59.56% quarter-over-quarter from 293.48% in Q4 2025.
GRI Bio (GRI) Return on Capital Employed (2021 - 2026) Analysis & Trends
GRI Bio's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 118.68% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 32612.0% year-over-year to 118.68%; the TTM figure through Mar 2026 stood at 118.68% (up 32612.0% YoY), while the FY2025 annual figure was 262.68%, up 4102.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 118.68%, up from 293.48% in the prior quarter.
- The five-year high for Return on Capital Employed was 118.68% in Q1 2026, with the low at 1158.39% in Q4 2023.
- The 5-year median for Return on Capital Employed is 340.41% (2023), against an average of 371.1%.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed plunged 68222 bps in 2023, then soared 95057 bps in 2024.
- GRI Bio's Return on Capital Employed stood at 476.17% in 2022, then slumped by 143 bps to 1158.39% in 2023, then surged by 82 bps to 207.82% in 2024, then sank by 41 bps to 293.48% in 2025, then soared by 60 bps to 118.68% in 2026.
- Business Quant data shows GRI's Return on Capital Employed at 118.68% in Q1 2026, 293.48% in Q4 2025, and 456.25% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | GRI Bio | 3.07 Mn | 3.07 Mn | - | -94.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -118.68% |
| Dec 31, 2025 | -293.48% |
| Sep 30, 2025 | -456.25% |
| Jun 30, 2025 | -393.49% |
| Mar 31, 2025 | -444.80% |
| Dec 31, 2024 | -207.82% |
| Sep 30, 2024 | -183.40% |
| Jun 30, 2024 | -239.83% |
| Mar 31, 2024 | -587.81% |
| Dec 31, 2023 | -1,158.39% |
| Sep 30, 2023 | -387.49% |
| Jun 30, 2023 | -387.33% |
| Dec 31, 2022 | -476.17% |
| Sep 30, 2022 | -130.46% |
| Jun 30, 2022 | -270.21% |
| Mar 31, 2022 | -201.91% |
| Dec 31, 2021 | -136.31% |
| Sep 30, 2021 | -79.59% |
| Jun 30, 2021 | -64.66% |
| Mar 31, 2021 | -116.44% |